October 2018

TP Therapeutics investment (drugging resistance mutations); Nasdaq listing of Arvinas [ARVN] (protein degradation); Revolutions Medicine’s acquisition of Warp Drive (precision medicine); IDEAYA Biosiences licenses Phase I compound from Novartis (targeting oncogenes)